Epidemiology and Management of Cysticercosis and *Taenia solium* Taeniasis in Europe, Systematic Review 1990–2011

Lorenzo Zammarchi¹, Marianne Strohmeyer¹, Filippo Bartalesi², Elisa Bruno³, José Muñoz⁴, Dora Buonfrate⁵, Alessandra Nicoletti³, Héctor Hugo García⁶, Edoardo Pozio⁷, Alessandro Bartoloni¹,²*, The COHEMI Project Study Group

Abstract

**Background:** Cysticercosis is caused by the invasion of human or pig tissues by the metacestode larval stage of *Taenia solium*. In Europe, the disease was endemic in the past but the autochthonous natural life cycle of the parasite is currently completed very rarely. Recently, imported cases have increased in parallel to the increased number of migrations and international travels. The lack of specific surveillance systems for cysticercosis leads to underestimation of the epidemiological and clinical impacts.

**Objectives:** To review the available data on epidemiology and management of cysticercosis in Europe.

**Methods:** A review of literature on human cysticercosis and *T. solium* taeniasis in Europe published between 1990–2011 was conducted.

**Results:** Out of 846 cysticercosis cases described in the literature, 522 cases were autochthonous and 324 cases were imported. The majority (70.1%) of the autochthonous cases were diagnosed in Portugal from 1983 and 1994. Imported cases of which 242 (74.7%) diagnosed in migrants and 57 (17.6%) in European travellers, showed an increasing trend. Most of imported cases were acquired in Latin America (69.8% of migrants and 44.0% of travellers). The majority of imported cases were diagnosed in Spain (47.5%), France (16.7%) and Italy (8.3%). One third of neurosurgical procedures were performed because the suspected diagnosis was cerebral neoplasm. Sixty eight autochthonous and 5 imported *T. solium* taeniasis cases were reported.

**Conclusions:** Cysticercosis remains a challenge for European care providers, since they are often poorly aware of this infection and have little familiarity in managing this disease. Cysticercosis should be included among mandatory reportable diseases, in order to improve the accuracy of epidemiological information. European health care providers might benefit from a transfer of knowledge from colleagues working in endemic areas and the development of shared diagnostic and therapeutic processes would have impact on the quality of the European health systems. Key words: cysticercosis, neurocysticercosis, *Taenia solium*, taeniasis, Europe, travellers, migrants.

Citation: Zammarchi L, Strohmeyer M, Bartalesi F, Bruno E, Muñoz J, et al. (2013) Epidemiology and Management of Cysticercosis and *Taenia solium* Taeniasis in Europe, Systematic Review 1990–2011. PLoS ONE 8(7): e69537. doi:10.1371/journal.pone.0069537

Editor: Sten H. Vermund, Vanderbilt University, United States of America

Received April 29, 2013; Accepted June 10, 2013; Published July 29, 2013

Copyright: © 2013 Zammarchi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was carried out within the COHEMI (COrdinating resources to assess and improve HEalth status of Migrants from Latin America)-projec.

This is a three-year collaborative project supported by the European Commission under the Health Cooperation Work Programme of the 7th FRAMEWORK PROGRAMME (GA-261495) launched in 2011 (http://www.cohemi-project.eu/). Héctor Hugo García is supported by a Wellcome Trust International Senior Research Fellowship in Tropical Medicine and Public Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: bartoloni@unifi.it

† Membership of the COHEMI Project Study Group is provided in the Acknowledgments

Introduction

Cysticercosis is due to the invasion of human or pig tissues by the metacestode larval stage of *Taenia solium* [1], a helminth that may reach of up to 8 m in length in the adult stage. *T. solium* is a zoonotic cestode which has a complex two host life cycle [1]. Humans are the only definitive hosts, harbouring the adult tapeworm in the gut without having significant symptoms [2]. The
adult tapeworm is acquired by eating raw or undercooked pork meat containing cysticerci [1]. Adult tapeworms have a life span of some years during which they produce millions of eggs which are intermittently released in the environment with the faeces [3–5]. Humans and pigs acquire cysticercosis ingesting T. solium eggs by the fecal-oral route [1]. After the ingestion, embryos contained in the eggs are released, cross the intestinal mucosa and are then transported by the circulatory system and dispersed throughout the body producing cysts mainly in the central nervous system (CNS) and in striated muscles [1]. Pigs are usually infected when reared in areas lacking adequate sanitary infrastructure where they can feed on human faeces [6].

Humans can acquire cysticercosis ingesting T. solium eggs released by themselves (autointestinak) or by another tapeworm carrier living with them or involved in the preparation of food [7,8]. In humans, the CNS is the most frequent localization of cysts which cause neurocysticercosis (NCC) [1]. NCC is considered to be the most common parasitic infection of the human nervous system and the most frequent preventable cause of epilepsy in the developing world [9] being responsible for about 30% of cases of epilepsy in low resources countries [10].

In several countries of Latin America, Africa and Asia, cysticercosis is highly endemic and linked to poverty, ignorance, lack of suitable diagnostic and management capacity and appropriate prevention and control strategies [9]. In these areas, cysticercosis leads to a very high economical burden related to losses in the meat industry for porcine cysticercosis, hospitalization costs for NCC and reduced productivity of people affected by NCC [2,11,12]. The situation is quite different in high resources countries such the United States and Europe. In the United States, cysticercosis has always been predominantly an imported disease and the number of observed cases increased from the 1990s onwards following the rise of immigration and the wide availability of the computerized tomography (CT) scan [13]. However in the period 1954–2005, 78 autochthonous cases have been reported in USA due to transmission from asymptomatic tapeworm carriers, who most likely acquired the infection abroad, to their household contacts [14].

In Europe, the disease was endemic in the past [15], but the natural life cycle of the parasite is currently completed very rarely thanks to the introduction of meat inspection, the progressive improvement of the pig husbandry, of the hygienic and socioeconomic conditions and consumers education [15,16]. Autochthonous cases of human and porcine cysticercosis are currently reported very rarely in Europe [17,19], while human imported cases emerged in the last two decades only when immigration from low resource countries towards this continent became consistent [19]. In Europe, cysticercosis is not covered by specific surveillance systems. The epidemiology of the taeniasis/cysticercosis in high resources countries is probably changing, but the lack of reliable data is one of the major obstacles to understand the magnitude of the problem and the relevance of the disease is probably underestimated.

COHEMI (COordinating resources to assess and improve HEalth status of MIgrants from Latin America) is a three-year collaborative project supported by the European Commission under the Health Cooperation Work Programme of the 7th FRAMEWORK PROGRAMME (GA-261495) launched in 2011 [http://www.cohemi-project.eu/]. The consortium brings together ten partners, six from Europe and four from Latin America (LA). One of the main objectives of the project is to provide a reliable estimate of the burden of selected Neglected Tropical Diseases in countries of origin and in different groups of migrants in Europe. The aim of this study is to review, scientific and grey literature on the epidemiology and management of autochthonous and imported cases of cysticercosis and T. solium taeniasis in Europe.

**Methods**

A review of indexed and grey literature on cysticercosis and T. solium taeniasis observed in Europe and published during the period 1990–2011 (July) was conducted. The data analysis focused on incidence and prevalence in the general population or special group of subjects, age and sex, infection rates, major clinical aspects, and country of infection.

The investigation covered 45 European countries, namely Albania, Andorra, Austria, Belarus, Belgium, Bosnia Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxemburg, Macedonia, Malta, Monaco, Moldova, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom and Vatican State.

**Search**

The following search strategy was adopted in PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), Embase (http://embase.com/home), The Cochrane Library (http://www.thecochranelibrary.com/); (cysticerc* OR neurocysticerc* OR cysticer* OR neurocisticerc* OR taenia* OR tenia* OR tapeworm) AND (Albania OR Andorra OR Austria OR Belarus OR Belgium OR Bosnia OR Herzegovina OR Bulgaria OR Cyprus OR Czech Republic OR Denmark OR Estonia OR Finland OR France OR Germany OR Greece OR Hungary OR Ireland OR Italy or Latvia OR Lithuania OR Luxemburg OR Malta OR Monaco OR Moldova OR Netherlands OR Poland OR Portugal OR Romania OR San Marino OR Serbia OR Slovakia OR Slovenia OR Spain OR Sweden OR United Kingdom OR Ukraine OR Switzerland OR Norway OR Russia OR Croatia OR Montenegro OR Iceland OR Turkey OR Macedonia OR Vatican State OR Europe) AND (Humans[Mesh] AND (“1990/01/01”[PDAT] : “2011/07/31”[PDAT])). The search has been performed in August 2011. The online abstract book database of European Congress of Clinical Microbiology and Infectious Diseases (ECCMID, http://www.blackwellpublishing.com/eccmid/) from 2000 to 2010 were also screened. Given the characteristics of the online abstract book database of ECCMID, it was queried using the following keywords “cysticercosis”, “neurocysticercosis” and “Taenia solium”. Moreover, additional published and unpublished studies from the authors were included together with data from the Ministry of Health (MoH) of the European authors’ countries (Spain and Italy) concerning the number of hospitalizations for cysticercosis in the national territories according to ICD9CM codes, since very few documents reported epidemiological data concerning cysticercosis in T. solium taeniasis in Europe.

**Selection**

The authors screened articles found by electronic search and evaluated their appropriateness based on title and abstract according to the established criteria. Exclusion criteria were: 1) studies concerning wrong agent (for example Taenia saginata or Echinococcus spp.); 2) reviews, letters or editorials without original data; 3) papers based on data only obtained through studies aiming to evaluate the performance of laboratory tests; 4) studies concerning animals only; 5) studies of European investigator outside the continent; 6) duplicated data; 7) articles with full texts
Table 1. Diagnostic criteria and degree of certainty for the diagnosis of neurocysticercosis according to Del Brutto et al. [20].

| Diagnostic criteria for neurocysticercosis | Degree of certainty for the diagnosis of neurocysticercosis** |
|-------------------------------------------|-------------------------------------------------------------|
| **Absolute** | **Definitive** | 1. Presence of one absolute criterion |
| 1. Histological demonstration of the parasite from biopsy of a brain or spinal cord lesion | 2. Presence of two major plus one minor and one epidemiologic criterion |
| 2. Cystic lesions showing the scolex on CT or MRI | 3. Presence of one major plus two minor criteria |
| 3. Direct visualization of subretinal parasites by funduscopic examination | 4. Presence of one major plus one minor and one epidemiologic criterion |
| **Major** | **Probable** | 1. Presence of one major plus two minor criteria |
| 1. Lesions highly suggestive of neurocysticercosis on neuroimaging studies* | 2. Presence of one major plus one minor and one epidemiologic criterion |
| 2. Positive serum EITB for the detection of anticysticercal antibodies | 3. Presence of three minor plus one epidemiologic criterion |
| 3. Resolution of intracranial cystic lesions after therapy with albendazole or praziquantel | |
| 4. Spontaneous resolution of small single enhancing lesions‡ | |
| **Minor** | | |
| 1. Lesions compatible with neurocysticercosis on neuroimaging studies§ | |
| 2. Clinical manifestations suggestive of neurocysticercosis\ | |
| 3. Positive CSF ELISA for detection of anticysticercal antibodies or cysticercal antigens | |
| 4. Cysticercosis outside the CNSenzyme-linked immunoelectrotransfer blot assay using purified extracts of Taenia solium antigens, as developed by the Centers for Disease Control and Prevention (Atlanta, GA). | |
| **Epidemiological** | | |
| 1. Evidence of a household contact with Taenia solium infection | |
| 2. Individuals coming from or living in an area where cysticercosis is endemic | |
| 3. History of frequent travel to disease endemic areas | |

Footnotes:

CT: Computed Tomography, MRI: Magnetic Resonance Imaging, EITB: Enzyme-linked immunoelectrotransfer blot assay, CSF: Cerebrospinal Fluid, ELISA: Enzyme-linked immunosorbent assay, CNS: Central Nervous System.

*CT or MRI showing cystic lesions without scolex, enhancing lesions, or typical parenchymal brain calcifications.

†Enzyme-linked immunoelectrotransfer blot assay using purified extracts of Taenia solium antigens, as developed by the Centers for Disease Control and Prevention (Atlanta, GA).

‡Solitary ring-enhancing lesions measuring less than 20 mm in diameter in patients presenting with seizures, a normal neurologic examination, and no evidence of an active systemic disease.

§CT or MRI showing hydrocephalus or abnormal enhancement of the leptomeninges, and myelograms showing multiple filling defects in the column of contrast medium.

\Seizures, focal neurologic signs, intracranial hypertension, and dementia.

enzyme-linked immunoelectrotransfer blot assay for the detection of anticysticercal antibodies.

**The presence of two different lesions highly suggestive of neurocysticercosis on neuroimaging studies should be considered as two major diagnostic criteria.

However, positive results in two separate types of antibody detection tests should be interpreted only on the basis of the test falling in the highest category of diagnostic criteria.

doi:10.1371/journal.pone.0069537.t001

written in languages other than that at least one of the members of the team could read and understand (namely English, French, Italian, German and Spanish). If the eligibility of the documents could not be ascertained according to the abstract and title only, the full text was analyzed to exclude or include the document. Moreover, in order to reduce possible underestimation of cysticercosis/T. solium taeniasis burden in some countries (mainly Eastern European countries), articles with an available English abstract, initially excluded due to the language of the full text, were selected as well.

Extraction

Data from epidemiological studies were summarized, while data from case reports and case series were extracted using a standardized electronic form in which the main characteristics of study, clinical and epidemiological features of subjects with cysticercosis and/or T. solium taeniasis were recorded. The form included all the information needed to ascertain whether cases of cysticercosis and of T. solium satisfied the definition of definitive, probable or possible case (reported below). Concerning English abstracts of articles initially excluded due to language limits, only information contained in the abstract and referred to the number of cases reported and the most likely place of infection was extracted.

Cases of cysticercosis and T. solium taeniasis retrieved by the search were classified according to the following definitions:

- **Definitive or probable case of neurocysticercosis:** according to the criteria shown in Table 1, which were proposed by Del Brutto [20]. A case confirmed through Polymerase Chain Reaction (PCR) on biopic specimen was also considered definitive;
- **Definitive case of cysticercosis outside of CNS:** case that was histologically confirmed by the presence of one or more cysticerci or PCR confirmed;
- **Possible case of cysticercosis or neurocysticercosis:** case reported by the authors as “cases of neurocysticercosis or cysticercosis”, but not fulfilling the criteria of definitive or probable case (for
example if sufficient data to classify the case as definitive or probable were not available);

- **Confirmed case** of *T. solium* taeniasis: *T. solium* taeniasis case in which the diagnosis was based on the detection of gravid proglottids with information on the number of the uterine branches or case in which the diagnosis of *Taenia* spp. was done in a patient with cysticercosis or NCC;

- **Possible case** of *T. solium* taeniasis: *T. solium* taeniasis case reported by the authors as “cases of *T. solium* taeniasis”, but not fulfilling the criteria of confirmed case;

- **Autochthonous case**: case diagnosed in a subject without history of travel to or living in high endemic regions (Latin America, Asia or Africa). A case in which the subject travelled in Europe was considered autochthonous;

- **Imported case**: case diagnosed in a subject with a history of travel or long stay in a endemic region (Latin America, Asia or Africa).

### Results

The flow diagram in Figure 1 shows the number of papers identified in each database and the review process. Out of 1967 screened documents, 166 were included: 40 on autochthonous cysticercosis [17,21–58], 7 on both autochthonous and imported cysticercosis [19,59–64], 16 on autochthonous *T. solium* taeniasis [65–80], 97 on imported cysticercosis [81–176], [Bartoloni A. unpublished], 4 on imported cysticercosis and *T. solium* taeniasis [7,177–179], and 2 on hospitalization for cysticercosis in Spain and Italy [180,181].

### Autochthonous Human Cysticercosis in Europe

Information on autochthonous cysticercosis originated from 47 papers [17,19,21–64]. According to a three year prospective study on the etiology of adult-onset epilepsy, carried out in Extremadura (Spain), 6.3% (5 of 80) of new cases of epilepsy were related to neurocysticercosis [57]. According to a seroprevalence study on 770 patients with epilepsy resident in Croatia, the seroprevalence was 1.5% using an ELISA test confirmed by an EITB (Enzyme-linked...
In Neigrar (Northern Italy), serum samples from 842 adopted children were tested to detect anti-\textit{T. solium} IgG by a commercial Enzyme-linked Immunosorbsent Assay (ELISA) [91], or EITB [12] or both tests (739), from 2001 to 2008; of them, 67 sera tested positive at least by one test (76 sera, 9.0%, by ELISA; 12 sera, 1.6% by EITB). When both tests were used, positive results were discordant for all sera but one (1 ELISA+/EITB–; 64 ELISA+/EITB–; 11 ELISA+/EITB not done; 11 EITB+/ELISA–). All the 87 seropositive infants underwent a cerebral MRI. Eight (4 EITB+/ELISA–, 2 ELISA+/EITB not done, 2 ELISA+/EITB–) showed abnormal findings which were compatible with NCC, but only three had symptoms (epilepsy). The two children with ELISA+/EITB– sera showed a single enhancing lesion and a lesion compatible with a gliotic scar by MRI. The seroprevalence of anti-\textit{T. solium} IgG in sera of Asian, Latin American, African, and European adopted children was 10.0%, 7.6%, 5.2%, 10.7% by ELISA and 1.7%, 0.0%, 2.6%, 0.0% by EITB, respectively [172].

Out of 108 studies, 324 cases of imported cysticercosis were described [7,19,59–64,81–170,172,174–179], [Bartoloni A., unpublished]; of them, 242 (74.7%) were migrants, 57 (17.6%) travellers, while no information was available for 25 cases (7.7%). Eleven (44.0%) travellers acquired the infection in Latin America, 10 (40.0%) in Asia (5 of whom in India), and 4 (16.0%) in Africa. The information was not available for 24 travellers or they had visited two or more endemic regions. Among migrants, 12 (5.1%) lived in more than one country before settling in Europe, therefore, it was not possible to know where they became infected.

The majority of migrants (157; 69.8%) were Latin American (including 86 from Ecuador, 18 from Peru, and 17 from Bolivia), while the others were equally distributed between Africa (34, 15.1%, including 11 from Capo Verde and 6 from Madagascar), and Asia (34, 15.1%, including 18 from India). The time elapsed between the last exposure in an endemic country and the onset of symptoms was reported for 158 subjects. Among them, 33 (22.9%) developed symptoms within one year from the last exposure, 106 (73.6%) between 2 and 5 years, 11 (7.6%) between 6 and 10 years and 8 (5.6%) after 11 or more years (Table 2, 3, 4 and Figure S1). The majority of imported cases of cysticercosis were diagnosed in Spain (47.5%), France (16.7%), Italy (8.3%) and United Kingdom (7.4%). Seventy to 80% of imported cases in Spain and Italy were diagnosed after 2000 while 80 to 90% of imported cases in France and the United Kingdom were diagnosed before 2000.

### Footnotes:

1. One study is still unpublished [Bartoloni A. unpublished].
doi:10.1371/journal.pone.0069537.002

### Table 2. Selected studies reporting autochthonous and imported cases of cysticercosis in Europe (1990–2011 July).

| Date of publication | Autochthonous | Imported |
|---------------------|--------------|----------|
| 1990–1994           | 14/46 (30.4%)| 16/108 (14.8%)|
| 1995–1999           | 6/46 (13.0%) | 20/108 (18.5%) |
| 2000–2004           | 14/46 (30.4%)| 28/108 (25.9%) |
| 2005–2009           | 11/46 (23.9%)| 35/108 (32.4%) |
| 2010–2011 July      | 1/46 (2.1%)  | 9/108 (8.3%)  |

#### First author field of activity

| Field                     | Autochthonous | Imported |
|---------------------------|--------------|----------|
| Neurology                 | 15/44 (34.1%)| 16/103 (15.5%)|
| Neurosurgery              | 8/44 (18.2%) | 11/103 (10.7%)|
| Infectious Diseases       | 4/44 (9.1%)  | 19/103 (18.4%)|
| Pathology or Microbiology | 4/44 (9.1%)  | 9/103 (8.7%)  |
| Parasitology              | 4/44 (9.1%)  | 9/103 (8.7%)  |
| Pediatrics                | 1/44 (2.3%)  | 11/103 (10.7%)|
| Neuroradiology            | 2/44 (4.5%)  | 7/103 (6.8%)  |
| Ophthalmology             | 1/44 (2.3%)  | 7/103 (6.8%)  |
| Other                     | 9/44 (20.4%) | 23/103 (22.3%) |

#### Notes:

- Autochthonous T. solium taeniasis in Europe

Only a confirmed case of \textit{T. solium} taeniasis in a 25 years old Italian farmer, was documented [65]. In this case the authors explicitly specified that the diagnosis was based on observation of a several series of proglottids identified as \textit{T. solium}. Forty-six cases of possible \textit{T. solium} taeniasis were reported from Poland, with at least two cases per year in the period 1997–2008 [69–80], while no cases were reported in 2009 [68]. In Albania, from 1982 to 2002, 18 possible cases of \textit{T. solium} were documented in 20 districts [67]. The only available study on the prevalence of \textit{T. solium} taeniasis was done in Szczecin Province (Poland) from 1994 to 1998. Only three \textit{T. solium} taeniasis cases of 331 intestinal taeniasis, mainly due to \textit{T. saginata} (n = 315), were documented. In this survey, prevalence of unspecified taeniasis decreased from 10.33/100,000 in 1994 to 3.52/100,000 in 1998 [66].

#### Imported Human Cysticercosis in Europe

There are only two studies on anti-cysticerci IgG in adopted children [172,179]. In Florence (Central Italy), 1090 adopted children, with a mean age of 5±3.4 years, were tested for anti-cysticerci IgG by a commercial EITB kit from 2001 to 2010, and the overall seroprevalence was 1% (0.3%, 1.8%, 1.6%, 0% in Asian, Latin American, African and European adopted children respectively). Mean age of seropositive children was higher than that of seronegative children (8±3.7 vs 5±3.3; p = 0.045). All seropositive infants (n = 11) underwent a neuroimaging study (CT scan or magnetic resonance imaging, MRI). Three presented abnormal findings compatible with neurocysticercosis, but only one had symptoms (epilepsy). The symptomatic child was a Peruvian female presenting also \textit{T. solium} tapeworm in stool [179].
Table 3. Main features of autochthonous and imported cases of cysticercosis in Europe (1990–2011 July).

|                          | Autochthonous | Imported |
|--------------------------|--------------|----------|
| Number of cases          | 522¹         | 324²     |
| Case diagnostic certainty|              |          |
| definitive               | 33/496 (6.7%)| 127/292 (43.5%) |
| probable                 | 29/496 (5.8%)| 66/292 (22.6%)  |
| possible                 | 434/496 (87.5%)³| 99/292 (33.9%)|
| Male sex                 |              |          |
| Male sex                 | 85/189 (45%) | 144/236 (61%)  |
| Mean age                 | 46.7±16.1    | 32.0±14.2 |
| Main symptoms            |              |          |
| asymptomatic             | 182/384 (47.4%) | 12/236 (5.1%) |
| epilepsy                 | 166/384 (43.2%) | 162/236 (68.6%)  |
| severe headache          | 14/384 (3.6%) | 39/236 (16.5%)  |
| others                   | 22/384 (5.7%) | 23/236 (9.7%)  |
| Main localization of cysts|              |          |
| Central Nervous System (CNS) | 492/496 (99.2%) | 276/292 (94.5%) |
| eye                      | 1/496 (0.2%) | 10/292 (3.4%)  |
| skin or soft tissues     | 3/496 (0.6%) | 6/292 (2%)    |
| Parasitological examination of stool showing taeniasis | 0/30 (0%) | 5/133 (3.8%) |
| Neuroimages pattern⁴     |              |          |
| cyst with scolex         | 3/276 (1.1%) | 38/188 (20.2%)  |
| cysts without scolex     | 75/276 (27.2%) | 54/188 (28.7%)  |
| enhancing lesions        | 23/276 (8.3%) | 49/188 (26%)  |
| calcifications           | 170/276 (61.6%) | 65/188 (34.6%)  |
| hydrocephalous           | 9/276 (3.3%) | 14/188 (7.4%)  |
| abnormal enhancement of leptomeninges | 3/276 (1.1%) | - |
| others                   | 2/276 (0.7%) | 9/188 (4.8%)  |
| Serology                 |              |          |
| positive on serum⁵       | 60/94 (63.8%) | 142/214 (66.4%) |
| positive on cerebrospinal fluid⁶ | 11/16 (68.7%) | 48/69 (69.6%)  |
| Treatment                |              |          |
| surgery only             | 23/115 (20%) | 19/254 (7.5%)  |
| surgery+antiparasitic    | 23/115 (20%) | 32/254 (12.6%)  |
| antiparasitic only       | 59/115 (51.3%) | 172/254 (67.7%)  |
| neither surgical nor antiparasitic treatment | 10/115 (8.7%) | 31/254 (12.2%)  |
| Indication for surgery (in neurocysticercosis) |              |          |
| ventriculo-peritoneal shunt for hydrocephalous | 8/29 (27.6%) | 16/46 (34.8%) |
| poor response to medical treatment | 1/29 (3.4%) | 2/46 (4.3%)  |
| excisional or incisional biopsy for suspected CNS neoplasm | 12/29 (41.4%) | 15/46 (32.6%) |
| spinal cyst              | 3/29 (10.4%) | 3/46 (6.5%)  |
| resections of ocular lesion | 1/29 (3.4%) | 6/46 (13%)  |
| excision of intraventricular cyst | 2/29 (6.9%) | 3/46 (6.5%)  |
| giant subarachnoid cyst  | 2/29 (6.9%) | 1/46 (2.2%)  |

Notes:
¹Cases published between 1990 and 2011 July but referred to cases diagnosed between 1980 and 2006. The majority (366, 70.1%) were diagnosed in Portugal from 1983 to 1994 [34,64].
²Cases published between 1990 and 2011 July but referred to case diagnosed between 1981 and 2009.
³Among this group, 348 subjects reported by Monteiro [34] were classified as “true” or probable, according to other criteria proposed by the same author in a previous paper [203].
⁴Each subject may have more than one neuroimaging pattern.
⁵EITB was used in 7 autochthonous and in 41 imported cases with positive serology on serum.
⁶EITB was used in 5 autochthonous and in 9 imported cases with positive serology on CSF.
doi:10.1371/journal.pone.0069537.t003
the number of hospitalizations by citizenship and by year as numerator and the number of residents in Italy by citizenship and by year as denominator [183], it was possible to estimate the hospitalization rate by 100,000 subjects in different groups. Considering the period 2001–2010, the higher mean hospitalization rate has been found in citizens from Latin America (5.9/100,000) and Asia (1.64/100,000), especially in Ecuadorian, Bolivian, Indian and Peruvian people (Table 5). According to the Spanish MoH from 2001 to 2009, the number of hospitalizations for suspected cases of cysticercosis ranged from 75 to 95 per year [180].

**Discussion**

The results of our findings, about epidemiology of *T. solium* taeniasis and cysticercosis in Europe, update those previously published by Overbosch et al. [184] and supplement those recently published by Del Brutto focusing on the epidemiology of NCC in Western Europe [185]. With respect to the latter review, our systematic research strategy included also grey literature and data from Eastern European countries, it was not limited to the CNS involvement, and focussed also on *T. solium* taeniasis. Moreover, data on the diagnostic and therapeutic management of the reported cases were also recorded.

Autochthonous cases of cysticercosis most of which were diagnosed in persons from the Mediterranean region (Iberian Peninsula, Italy and Balkans), are decreasing. In fact, most of these cases (366, 70.1%) were reported in Portugal from 1983 to 1994 [34,64]. Persons who acquired cysticercosis in Europe were older than those who acquired cysticercosis abroad, and were more frequently asymptomatic, often presenting brain calcifications (the end-stage inactive lesion of cysticercosis) and without taeniasis. These clinical data suggest that these people acquired the infection in a remote past.

Our literature investigation does not allow to know whether the *T. solium* cycle is still active in Europe. Since *T. solium* taeniasis is acquired by eating insufficiently cooked pig meat with cisticerci, the presence in the European regions of porcine cysticercosis is the “condition sine qua non” to acquire *T. solium* taeniasis in Europe. The importation of cisticercus-infected pork can be excluded due to the veterinary controls, through meat inspection performed at slaughterhouse, and the circulation of cisticercus-infected pigs exists only in small and poor areas of the world where pigs are used only for local consumption and which do not trade at the international level.

Our search retrieved 68 cases of *T. solium* taeniasis in native European persons, the large majority of which (67.6%) have been reported from Poland. At the diagnosis, *T. solium* taeniasis may be confused with the very common *T. saginata* which is circulating with a 0.01–2% prevalence in Western Europe and with a higher prevalence in Eastern Europe [186]. By morphology, *T. solium* and *T. saginata* eggs are indistinguishable between them and the two Taeniidae species can be distinguished only by the count of the uterine branches in the proglottids or by the scolex which, however, is very rarely detectable [187]. Specific faecal antigen detection or PCR method are not yet performed in clinical practice and, to our knowledge, were never used for an epidemiological study in Europe.

To date in Western Europe, intensive indoor pig productions largely predominate. However, the increasing trend to produce organic pork from free-ranging pigs could increase the risk of *T. solium* transmission [188], and could represent a reason of concern for the control of cysticercosis in Europe. In 2007, a survey of the European Food Safety Authority, among European Union countries members, showed that porcine cysticercosis was still present in several countries (Belgium, Czech Republic, Denmark, Germany, Italy, Luxembourg, the Netherlands, Portugal and the United Kingdom), whereas no information was available for the other 11 EU countries [18]. This survey suggests that *T. solium* taeniasis is still circulating in Europe; however, these data should be carefully interpreted because porcine cysticercosis due to the larval stage of *Taenia hydatigena* can be misdiagnosed with the infection caused by larvae of *T. solium*. The absence of porcine cysticercosis recently reported in Portugal [18], where an hotspot of cysticercosis transmission was observed up to early nineties [34], suggests the possible interruption of transmission due to the modification of breeding conditions adopted in the recent years. Autochthonous cases of cysticercosis in Europe could also originate from *T. solium* carriers (migrant or traveller) who acquired taeniasis outside

### Table 4. Autochthonous and imported cases of cysticercosis in Europe by country of diagnosis (1990–2011 July).

| Country of diagnosis | Autochthonous | Imported |
|----------------------|--------------|----------|
| Austria              | 1/522 (0.2%) | 1/324 (0.3%) |
| Belgium              | –            | 1/324 (0.3%) |
| Croatia              | 8/522 (1.5%) | –         |
| Czech Republic       | –            | 10/324 (3.1%) |
| Denmark              | –            | 1/324 (0.3%) |
| Finland              | –            | 1/324 (0.3%) |
| France               | 2/522 (0.4%) | 54/324 (16.7%) |
| Germany              | 7/522 (1.3%) | 15/324 (4.8%) |
| Greece               | 3/522 (0.6%) | –         |
| Hungary              | –            | 2/324 (0.6%) |
| Ireland              | –            | 2/324 (0.6%) |
| Italy                | 7/522 (1.3%) | 27/324 (8.3%) |
| Latvia               | 1/522 (0.2%) | 1/324 (0.3%) |
| Luxembourg           | 1/522 (0.2%) | –         |
| Norway               | 1/522 (0.2%) | 3/324 (0.9%) |
| Poland               | 8/522 (15.3%) | – |
| Portugal             | 366/522 (70.1%) | 20/324 (6.2%) |
| Spain                | 35/522 (6.7%) | 154/324 (47.5%) |
| Serbia               | 78/522 (14.9%) | –         |
| Switzerland          | 2/522 (0.4%) | 4/324 (1.2%) |
| The Netherlands       | –            | 4/324 (1.2%) |
| Turkey               | 1/522 (0.2%) | –         |
| United Kingdom       | 1/522 (0.2%) | 24/324 (7.4%) |

**Notes:**
Cases reported from Austria [39], Luxembourg [23], Norway [59], Switzerland [29], two case from Germany [31,38] and one case from Spain [61] were diagnosed in subjects who travelled to or resided in other European countries. Concerning 348 cases reported from Portugal [34], the authors do not specify whether all cases are autochthonous, but state in the introduction that the catchment area of the hospital is highly endemic (district of Oporto and north inland). Concerning 181 cases reported from Poland. At the diagnosis, Taenia hydatigena can be misdiagnosed with the infection caused by Taenia hydatigena.
Europe as observed in the United States [8,14]. In our search, we found only 5 cases of *T. solium* immigrant carriers. Consequently, we can speculate that the risk of spreading cysticercosis in Europe from an asymptomatic tapeworm carriers coming from abroad is quite low even if it cannot be excluded.

The larval stage of *Taenia crassiceps, Taenia multiceps* and *Taenia serialis* infecting canids as final host and rodents, rabbits, sheep and goats as intermediate host can sporadically affect humans in Europe. In some cases, neither pathological examination nor serology can differentiate these parasites from *T. solium* cysticerci [50]. Therefore, we cannot exclude that a portion of cases diagnosed as cysticercosis in Europe has been caused by other species of cestodes.

In Europe, the increasing number of migrants from low resource countries (74.7% of cysticercosis imported cases) and international travellers (17.6% of imported cases) resulted in an increase of cysticercosis. Most of imported cases originated from Latin America, where 44.0% of affected travellers and 69.8% of affected migrants acquired the infection. Most of individuals with imported disease developed symptoms after 2 to 5 years after migration. This finding is quite similar to that obtained in the classic epidemiological studies carried out in the sixties in English soldiers returning from India [189], confirming that the incubation period of cysticercosis, even if largely variable, is usually between 2 to 5 years.

The European countries where cysticercosis cases are more often imported are those with larger immigration such as Spain, France, Italy and the United Kingdom. Spain is the country reporting the highest number of imported cases of cysticercosis, probably because it hosts the largest number of Latin American migrants in Europe.

Considering both autochthonous and imported cases, neurologists, infectious disease specialists, neurosurgeons, laboratory specialists (microbiologists, parasitologists, pathologists), paediatricians and radiologists were the most often involved persons in the management of people with cysticercosis in Europe. This wide range of specialists confirms the need of knowledge in different settings to manage cysticercosis. NCC is certainly the parasite localization which is managed with more difficulties since there is not a gold standard test for the diagnosis but only diagnostic criteria and no treatment of choice but only recommendation to tailor the therapy case by case [190].

From the clinical point of view, NCC does not shows any pathognomonic signs or symptoms. On the contrary, it may present with nearly all neurological signs or symptoms [191,192]. Neuroradiological images are pathognomonic only in few cases when the scolex is visible in the cyst (named “cyst with dot” image) [20]. Serological tests didn’t help too much. Several serological assays to detect specific antibodies have been used for decades with different and somewhat conflicting results [193,194]. Currently, most centres use an EITB with purified glycoprotein antigens [195], which can be performed on serum samples or on cerebrospinal fluid (CSF) or use an ELISAs. The EITB sensitivity in serum samples is equal to or better than that in CSF samples [196]. Although EITB has 100% specificity and a sensitivity of 98% in patients with two or more cerebral lesions, up to 50% of patients with a single brain lesion or with only calcified parasites may test negative [197–199]. The main problem related to ELISA is that it is the poor specificity which is reported around 70% or less [194]. In any case, serological results must be carefully interpreted together with the other diagnostic criteria. So far, EITB positivity on serum is considered to be a major diagnostic criterion and ELISA positivity on CSF a minor diagnostic criterion [20]. Recently, a serum antigen detecting ELISA has been reported to have an acceptable sensitivity (83–100%) and specificity (84–96%) proposed as an adjunctive tool for the diagnosing NCC [200].

The diagnostic delay can be huge. In one person, NCC was misdiagnosed with migraine, cluster headache, and viral meningitis for 29 years after the onset of symptoms [111]. Parenchymal NCC can be misdiagnosed with brain tumour and lead to avoidable surgery as in the two cases reported by Bouillot [163]. About one third of neurosurgical operations reported in the examined literature, were probably avoidable since the indication to surgery was not among that are commonly accepted [200]. In autochthonous and imported cases of cysticercosis, 41.4% and 32.6% of operations, respectively, were performed for suspected CNS neoplasm. This high rate of neurosurgical interventions can be attributed to the low awareness and experience in management of the disease and the inadequacy of preoperative diagnostic tools [43].

### Table 5. Hospitalization for cysticercosis in Italy, 2001–2010 [181,183].

| Number of hospitalizations for cysticercosis (2001–2010) | Estimated mean hospitalization rate for cysticercosis by citizenship (n/100,000) (2001–2010) |
|-----------------------------------------------------------|-------------------------------------------------------------------------------------|
| All residents in Italy                                    | 0.09                                                                               |
| Italians citizens                                         | 0.05                                                                               |
| Citizens of Latin American countries                     | 5.90                                                                               |
| Ecuadorian                                                | 13.70                                                                              |
| Peruvians                                                 | 5.57                                                                               |
| Bolivians                                                 | 42.79                                                                              |
| Citizens of African countries                             | 0.55                                                                               |
| Citizens of Asian countries                               | 1.64                                                                               |
| Indians                                                   | 10.18                                                                              |
| Citizens of European countries (except Italy)             | 0.09                                                                               |

References:

162. Ministero della Salute Dipartimento della Qualità Direzione Generale Programmazione Sanitaria (2011) Dati estratti dalla banca dati delle schede di dimissione ospedaliera anni 2001–2010 per il progetto COHEMI. DGPROG 1.9.0.3. Italy.

163. Istituto Nazionale di Statistica (2011) Cittadini stranieri. Bilancio Demografico e popolazione residente straniera al 31 dicembre per sesso e cittadinanza. doi:10.1371/journal.pone.0069537.t005
According to Ruiz [154], 22.8% (8 of 35) of persons received albendazole in spite of not having antiparasitic treatment indication. Finally, it should be stressed that the treatment of NCC cannot be limited to surgery and/or antiparasitic drugs. The symptomatic therapy including anti-inflammatory drugs (corticosteroids), analgesics, adequate antiepileptic treatment as for other secondary epilepsies, represents the main measure in the management of NCC; however, these important treatment issues are rarely discussed in case reports [202].

Conclusions: In Europe we are currently observing the overlapping of two epidemiological pictures of cysticercosis/T. solium taeniasis: the autochthonous and the imported infections. Autochthonous cases are disappearing, while imported cases are rising as a consequence of travels and migrations. Given the lack of systematic epidemiological data collection and disease reporting, the magnitude of the phenomenon cannot be delineated. Moreover, it is unclear if cases of imported T. solium taeniasis are now generating autochthonous cases of cysticercosis but, according to our search, it is probably a limited problem. In order to get more information, policy makers should consider to include cysticercosis among mandatory reportable diseases. From the clinical point of view, NCC remains a challenge for clinicians despite their full access to all the available tools for diagnosis and management of the disease. The currently available diagnostic tests and treatment options are frequently insufficient and research activities in this field are strongly needed. Within a perspective of a south-north and north-south cooperation, European health care providers might benefit from a transfer of knowledge from expert colleagues working in endemic areas and the development of shared diagnostic process and therapeutic decisions would have impact on the European health systems quality.

**Supporting Information**

**Figure S1** Maps showing the geographical distribution by country of diagnosis of autochthonous and imported cases of cysticercosis reported in Europe (1990–2011 July).

| Table S1 | PRISMA Checklist. |
| --- | --- |
|  | (DOC) |

| Table S2 | PRISMA Flowchart. |
| --- | --- |
|  | (DOC) |

**Acknowledgments**

Authors thank the COHEMI project study group that includes: Maurizio Bonati, Chiara Pandolfini, Francesca Severino, Valeria Confalonieri, Gianni Tognoni, Zeno Bisioli, Dora Buonfrate, Andrea Angheben, Marco Albonico, Alessandro Bartolini, Marianne Strohmeyer, Lorenzo Zambrilli, Filippo Bartalesi, Jose Muñoz, Ana Requena-Mendez, María Roura, Laia Ventura, Robert Pool, Christopher Pell, Anita Hardon, Peter Chiodini, Juan Moreira, Mariella Anselmi, Roberto Semprètégui, Eduardo Gotuzzo, Maria Alejandra Mená, Carola Liendo, Héctor H. García, Javier Bustos, Saul Santiviández, Faustino Torrico, Daniel Lozano, Teresa Hinojosa Cabrera, Javier Ochoa Morón, Ignacio Abapori Cuellar, Jaime Animuz Soreaze, Guido Chumiray Rojas, Alessandra Nicoletti, Elisa Bruno.

Authors thank Doctor Giorgio Zavarise for providing assistance with data collection at the “Dipartimento di Pediatria, Ospedale Sacro Cuore, Negrar, Verona, Italy”; Doctor Francesco Bevere (Ministero della Salute, Direttore Generale della Programmazione Sanitaria, Roma Italy) and Engineer Pietro Granella (Ministero della Salute Dipartimento della Qualità, Direzione Generale Programmazione Sanitaria, Specialista del settore Statistico Informatico, Roma, Italy) for providing data on hospitalization for cysticercosis/taeniasis in Italy (ICD9CM classification); mister Marco Miranda, who kindly assisted with the preparation and proof-reading of the manuscript.

Héctor Hugo Garcia is supported by a Wellcome Trust International Senior Research Fellowship in Tropical Medicine and Public Health.

**Author Contributions**

Conceived and designed the experiments: LZ MS FB EB JM DB AN HHG EP AB. Performed the experiments: LZ MS AB EP HHG. Analyzed the data: LZ MS AB EP HHG. Wrote the paper: LZ MS HHG EP AB.

**References**

1. Garcia HH, Del Brutto OH (2000) Taenia solium cysticercosis. Infect Dis Clin North Am 14: 97–119, ix.
2. Pawlowski Z, Allan J, Sarti E (2005) Control of Taenia solium taeniasis/ cysticercosis: from research towards implementation. Int J Parasitol 35: 1221–1232.
3. Allan JC, Velazquez-Tolom M, Garcia-Navar J, Torres-Alvarez R, Yurrita P, et al. (1996) Epidemiology of intestinal taeniasis in four, rural, Guatemalan communities. Am Trop Med Parasitol 90: 137–165.
4. Allan JC, Velazquez-Tolom M, Torres-Alvarez R, Yurrita P, Garcia-Navar J (1996) Field trial of the coproantigen-based diagnosis of Taenia solium taeniasis by enzyme-linked immunosorbent assay. Am J Trop Med Hyg 54: 352–356.
5. Garcia HH, Gilman RH, Gonzalez AE, Verastegui M, Rodriguez S, et al. (2003) Hyperendemic human and porcine Taenia solium infection in Peru. Am J Trop Med Hyg 68: 260–273.
6. Carpio A (2002) Neurocysticercosis: an update. Lancet Infect Dis 2: 751–762.
7. Bourke GJ, Petana WB (1994) Human Taenia cysticercosis: a bizarre mode of transmission. Trans R Soc Trop Med Hyg 88: 609.
8. Schantz PM, Moore AC, Munoz JL, Hartman BJ, Schaefer JA, et al. (1992) Neurocyticercosis in an Orthodox Jewish community in New York City. N Engl J Med 327: 692–695.
9. Willingham AL, 3rd, Engels D (2006) Control of Taenia solium cysticercosis/ taeniasis. Adv Parasitol 61: 369–566.
10. Ndembuzanzo PC, Carabin H, Basile CM, Nguyen H, Qian YJ, et al. (2010) A systematic review of the frequency of neurocysticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis 4: e870.
11. Torgerson PR, Macpherson CN (2011) The socioeconomic burden of parasitic zoonoses: global trends. Vet Parasitol 182: 79–93.
12. Rajkotia Y, Lescano AG, Gilman RH, Cornejo C, Garcia HH (2007) Economic burden of neurocysticercosis: results from Peru. Trans R Soc Trop Med Hyg 101: 840–846.
13. Shandrea WX, Schantz PM, White Jr AC (2002) Taenia solium Cysticercosis: the special case of United States. In: Singh G, Prabhakar S, editors. Taenia Solium Cysticercosis: From Basic to Clinical Science. UK: CABP Pub. 139–144.
14. Sorvillo F, Wilkins P, Shafir S, Eberhard M (2011) Public health implications of cysticercosis acquired in the United States. Emerg Infect Dis 17: 1–6.
15. Hinz E (1993) Current status of food-borne parasitic zoonoses in West Germany. Southeast Asian J Trop Med Public Health 24 Suppl: 78–84.
16. Pozio E (2008) Epidemiology and control prospects of foodborne parasitic zoonoses in the European Union. Parasitologia 50: 17–24.
17. Breschi F, Gianagosto F, Castagna M, Becherini F, Filice ME, et al. (2006) Neurocysticercosis: surgical treatment of an autochthonous case in a non-endemic region. Pathologica 98: 229–231.
18. Dorný P, Vallée I, Alain L, Boes J, Boireau P, et al. (2010) Scientific Report submitted to EFSA. Development of harmonised schemes for the monitoring and reporting of Cysticercus in animals and foodstuffs in the European Union. European Food Safety Authority.
19. Ezquivel A, Díaz-Otero F, Gómez-Rodrán S (2005) Growing frequency of neurocysticercosis in Madrid (Spain). Neurologia 20: 116–120.
20. Del Brutto OH, Rajphlıkhar V, White AG, Jr., Tsang VC, Nash TE, et al. (2001) Proposed diagnostic criteria for neurocysticercosis. Neurology 57: 177–183.
21. Palais S, Deveverelas A (1991) Extramedullary spinal cysticercosis. Eur J Radiol 12: 216–218.
22. Schmidt E, Klaus V, Stefaní HH (1990) [Unilateral iritis by cysterceral larva in the anterior chamber]. Ophthalmologica 204: 200–210.
23. Sandt G, Beisl L, Kölgen A (1990) [Cysticercosis of the 6th ventricle]. Bull Soc Sci Med Grand Duche Luxembourg 127: 45–49.
24. Mancuso P, Citrano I, Tospe R (1991) Neurocysticercosis treated with praziquantel. Long-term follow-up of a case. J Neurol Neurosurg Psychiatry 54: 157–160.
25. Jimenez-Jimenez FJ, Molina-Arjona JA, Roldan-Montaud A, Aguila A, Santos J, et al. (1992) Blefharospasms associated with neurocysticercosis. Acta Neurol [Napoli] 14: 56–59.
26. Fandino J, Botana C, Fandino C, Rodriguez D, Gomez-Bueno J (1991) Clinical and radiographic response of fourth ventricle cysticercosis to praziquantel therapy. Acta Neurochir (Wien) 111: 135–137.

27. Ishido-Llorens A, Dachs F, Vidal J, Sarrias M (1993) Spinal cysticercosis. Case report and review. Paraplegia 31: 128–139.

28. Saporiti A, Brochieri A, Grignani G (1995) Neurocysticercosis and epilepsy. Description of a clinical case. Minerva Med 85: 403–407.

29. Bauer TM, Bruhwiler J, Aschwanden M, Wagner S, Schindler J (1994) Neurocysticercosis revisited. Dtsch Med Wochenschr 119: 175–179.

30. Waldvogel F, Korner F, Terrier F (1994) [Mucous ache and vision disorders in a South American immigrant to Switzerland]. Praxi (Bern) 1994: 83: 1413–1417.

31. Roos G, Heunze T, Gullotta F, Oehler U, Dreyhaupt G (1995) [Neurocysticercosis: a long-term follow-up of 143 patients]. Acta Neurochir Suppl 62: 33–40.

32. La Mantia L, Costa A, Eoli M, Savioardo M (1995) Racemose neurocysticercosis after chronic meningitis: effect of medical treatment. Clin Neurol Neurosurg 97: 50–54.

33. Maddalena G, Nozolli C, Passarella B (1995) Neurocysticercosis treated with albendazole long term follow-up of a case. J Neurosurg Sci 39: 171–175.

34. Monteiro L, Nunes B, Mendonca D, Lopes J (1995) Spectrum of epilepsy in neurocysticercosis: a long-term follow-up of 143 patients. Acta Neurochir Suppl 62: 51–56.

35. Titlic M, Tonkic A, Jukic I, Lahman-Doric M, Kolic K, et al. (2007) Electroencephalographic findings in cerebral cysticercosis patients. [12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, UK]. J Med Microbiol 63: 321–324.

36. Fandino J, Botana C, Fandino C, Rodriguez D, Gomez-Bueno J (1991) Clinical and radiographic response of fourth ventricle cysticercosis to praziquantel therapy. Acta Neurochir (Wien) 111: 135–137.

37. Castellanos F, Montes I, Porras LF, Peragallo E, Ampuero J, et al. (2000) [Neurocysticercosis: an imported disease?]. Med Clin (Barc) 118: 77.

38. Ogilvie CM, Kasten P, Rovinsky D, Workman KL, Johnston JO (2001) Cerebral cysticercosis and epilepsy. Neurosurg 97: 50–54.

39. Wraige E, Graham J, Robb SA, Jan W (2003) Neurocysticercosis masquerading as a cerebral infarct. J Child Neurol 18: 298–300.

40. Ogilvie CM, Kasten P, Rovinsky D, Workman KL, Johnston JO (2001) Cerebral cysticercosis and epilepsy. Neurosurg 97: 50–54.

41. La Mantia L, Costa A, Eoli M, Savioardo M (1995) Racemose neurocysticercosis after chronic meningitis: effect of medical treatment. Clin Neurol Neurosurg 97: 50–54.

42. Isidro-Llorens A, Dachs F, Vidal J, Sarrias M (1993) Spinal cysticercosis. Case report and review. Paraplegia 31: 128–139.

43. Talan-Hranilovic J, Sajko T, Negovetic L, Lupret V, Kalousek M (2002) Electroencephalographic findings in cerebral cysticercosis patients. [12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, UK]. J Med Microbiol 63: 321–324.

44. Carangelo R, Erra S, Del Basso De Carlo ML, Bocciero A, Vizioli L, et al. (2001) Neurocysticercosis. Case report. J Neurol Neurosurg Psychiatry 74: 43–46.

45. Ponzanelli R, Ferrigno P, Ferrari MR, Murgia SB (2001) Seizure disorder mimicking an acute confusional state as clinical presentation of neurocysticercosis: neuroimaging, EEG findings and clinical correlations. Neurol Sci 22: 159–163.

46. Talar-Hranilovic J, Sajko T, Negovetic L, Lupret V, Kalousek M (2002) Electroencephalographic findings in cerebral cysticercosis patients. [12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, UK]. J Med Microbiol 63: 321–324.

47. Vidal J, Sarrias M (1993) Spinal cysticercosis. Case report and review. Paraplegia 31: 128–139.

48. Wraige E, Graham J, Robb SA, Jan W (2003) Neurocysticercosis masquerading as a cerebral infarct. J Child Neurol 18: 298–300.

49. Brunette ML, Barrera Y, Avila A, Nolte S, Jones J, et al. (1997) Single case report of praziquantel treatment of neurocysticercosis following a possible re-infection in a travel-immigrant patient. J Infect Dis 176: 1413–1417.

50. Barros J, Barros Jr J, Castro PA, Cunha CR, da Fonseca MJ (2000) Neurocysticercosis mimicking glioblastoma multiforme: a rare differential diagnosis in Central Europe. Neuroradiology 43: 227–230.

51. Wraige E, Graham J, Robb SA, Jan W (2003) Neurocysticercosis masquerading as a cerebral infarct. J Child Neurol 18: 298–300.

52. Wraige E, Graham J, Rovinsky D, Workman KL, Johnston JO (2001) Cerebral cysticercosis and epilepsy. Neurosurg 97: 50–54.

53. Ogilvie CM, Kasten P, Rovinsky D, Workman KL, Johnston JO (2001) Cerebral cysticercosis and echinococcosis: a preoperative diagnostic dilemma. Arch Med Res 33: 590–594.

54. Wraige E, Graham J, Robb SA, Jan W (2003) Neurocysticercosis masquerading as a cerebral infarct. J Child Neurol 18: 298–300.

55. Plonka W (1999) [Cestode infections in 1997]. Przegl Epidemiol 53: 159–165.

56. Dietrichs E, Tyssvang T, Aanonsen NO, Bakke SJ (1993) Cerebral cysticercosis mimicking glioblastoma multiforme: a rare differential diagnosis in Central Europe. Neuroradiology 43: 227–230.
124. Ramos JM, Masia M, Padilla S, Bernal E, Martin-Hidalgo A, et al. (2007) Fatal cysticercosis in a female Nicaraguan patient. J. Infect. Dis. 206: 1–123.
123. Guevara del Barrio E, Lopez Roger R (2007) Intracerebral cystic lesion in an immigrant patient. Rev. Clin. Esp. 207: 301–302.
122. Creutzfeldt J, Fuchs G, Matsumura R, et al. (2007) Cysticercosis in a female Nicaraguan traveler. J. Travel Med. 14: 349–351.
121. Costa GU, Vioque J, Juncos A, et al. (2007) [Neurocysticercosis: a rare case of a tumor of the tongue]. Laryngorhinootologie 86: 564–567.
120. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
119. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
118. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
117. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
116. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
115. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
114. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
113. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
112. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
111. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
110. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
109. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
108. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
107. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
106. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
105. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
104. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
103. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
102. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
101. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
100. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
99. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
98. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
97. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
96. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
95. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
94. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
93. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
92. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
91. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
90. Guionnet P, Lassoued M, et al. (2007) [Intracerebral cysticercosis: a differential diagnosis with cerebral metastasis]. Rev. Neurol. 213: 197–200.
